Publicacións nas que colabora con Carlos López López (10)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

2022

  1. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2020

  1. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?

    International Journal of Colorectal Disease, Vol. 35, Núm. 4, pp. 739-746

  2. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750

2019

  1. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis

    Oncologist, Vol. 24, Núm. 8, pp. e687-e695

2018

  1. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

  2. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

    Gastric Cancer, Vol. 20, Núm. 3, pp. 465-474

2015

  1. Clinical guideline SEOM: hepatocellular carcinoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 988-995

  2. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

    Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 731-737